MJ Enterprises (MJTV): A Better Bet on Cannabis Therapeutics
Ryan Allway
August 17th, 2016
News, Top Story
The Drug Enforcement Administration (“DEA”) dashed hopes for federally-relaxed marijuana laws in August. Despite mounting scientific evidence, the drug czar decided to keep marijuana as a Schedule I Controlled Substance that has ‘no currently accepted medical value’. The irony is that the FDA had already approved a cannabinoid – dronabinol – back in 1985, while GW Pharmaceuticals’ (NASDAQ: GWPH) Epidiolex has shown tremendous promise for seizures.
The decision is certainly a setback for the cannabis movement, but there are several companies that could benefit from the classification. Pharmaceutical companies that leverage cannabinoids benefit from mounting clinical evidence of safety and efficacy. Once approved, these companies can charge premium prices for their cannabinoid-based therapeutics without having to worry about competition from widely available medical marijuana.
In this article, we will take a look at Michael James Enterprises Inc. (OTC: MJTV) and its plans to reformulate and enhance the delivery of dronabinol to target sleep disorders.
Cannabinoids for Sleep Disorders
Michael James Enterprises acquired the rights and intellectual property to develop and market therapeutics for sleep disorders using the cannabinoid dronabinol as the base ingredient in early August. After its FDA approval back in 1985, Marinol® – the brand name controlled by AbbVie Inc. (NYSE: ABBV) – reach peak sales of $100 million in 2007 with dronabinol-based generics reaching $135 million in sales last year, according to IMS.
More than half of Americans report symptoms of insomnia a few nights a week or more, according to the National Sleep Foundation. A growing body of evidence suggests that tetrahydrocannabinol – or THC – may be effective in treating sleep disorders by facilitating a relaxed state of alpha-dominated waves through the adenosine pathway. The University of Illinois-Chicago’s Phase IIB clinical trials for sleep apnea should confirm these findings.
Michael James Enterprises’ proprietary formulation of dronabinol includes another active ingredient that has shown promise in pre-clinical studies. Management plans to progress its proprietary treatment through clinical trials and commercialize treatments across various sleep disorders. In the future, the company also plans to develop additional formulations of dronabinol targeting other medical indications where cannabinoids have shown promise.
Innovative Delivery Mechanism
Michael James Enterprises recently announced the purchase of a master advising agreement with HealthPartners’ William H. Frey, II, PhD., who is an expert in intranasal delivery. Dr. Frey will serve as one of the company’s scientific advisors and provide key insights to his non-invasive intranasal method for bypassing the blood-brain barrier to rapidly deliver and target therapeutic agents to the brain without unwanted side effects.
Since its dronabinol-based therapeutic acts on adenosine pathways in the brain, an intranasal delivery method could significantly improve the efficacy of the drug and set it apart from others in the space. The same delivery mechanism could be used for future dronabinol-based therapeutics that target other brain-related conditions. The company maintains the rights to all documentation and work product from its relationship with Dr. Frey under the agreement.
CEO James Farinella indicated that the company will continue to bring in top medical and scientific minds in order to ensure the ‘highest likelihood of success’ for the company and its shareholders. The company’s press release hinted that these new additions could be announced over the coming weeks and months. As the company gears up for clinical trials, these relationships could help set its sleep therapeutic apart and drive long-term success.
Looking Ahead
The DEA’s decision to keep marijuana as a Schedule I Controlled Substance may be bad news for cannabis advocates, but it’s not necessarily bad news for pharmaceutical companies involved in the space. Working with the FDA-approved cannabinoid dronabinol, Michael James Enterprises is embarking on a low-risk strategy develop and market a sleep therapeutic with a novel active ingredient, and potentially, a novel intranasal delivery system.
For more information, visit the company’s website at www.mjenterprises.com or view the company’s regulatory filings on OTC Markets.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
DNA Genetics has built and curated a seasoned genetic library and developed proven standard operating procedures for genetic selection, breeding, and cultivation.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
